Sofosbuvir, velpatasvir, veloxpravir efficacy in 12-week treatment in triple infected (chronic hepatitis C, chronic hepatitis B, and HIV) geno 3 naive population: An open lable prospective clinical trial-(SOLVVE-c)

Authors
Category Primary study
ConferenceHepatology
Year 2018
This article has no abstract
Epistemonikos ID: deb481d4c9a00a4b93d107b03db2da519ced30d5
First added on: Apr 29, 2026